FDA Approves First-Ever Gene Therapy for Deafness and 80 Percent of Kids Could Hear Within a Year

Travis used to sleep through everything. Then his mother laughed in the car and woke him up, the first time he had ever heard her voice. About three months earlier, Travis had received an experimental treatment for genetic deafness as part of a clinical trial.

On April 23, 2026, the FDA approved that treatment, making it the first gene therapy for hearing loss ever cleared in the United States. The therapy is called Otarmeni, developed by Regeneron Pharmaceuticals, and the company has said it will provide it free of charge to U.S. patients.

In the clinical trial behind the approval, 80 percent of the 20 evaluable children showed measurable hearing improvement within a year. Forty-two percent could detect whispered speech. The condition Otarmeni treats affects roughly 50 infants born in the United States each year, and until this approval, no treatment existed that addressed the underlying cause.

A Protein Gap That Cuts the Signal Short

Otoferlin deafness stems from mutations in the OTOF gene, which produces a protein called otoferlin. That protein acts as a relay inside the cochlea, the spiral structure of the inner ear, triggering the electrical signal that travels from the ear’s hair cells to the brain. In children born with two defective copies of the gene, no functional otoferlin is produced. The ear detects sound. The signal never leaves.

The condition accounts for 2 to 8 percent of all inherited hearing loss cases. Delayed diagnosis adds to the damage, since children who go undetected lose critical windows for speech and language development. Before Otarmeni, the only option was a cochlear implant, a device that converts sound into electrical pulses sent directly to the auditory nerve.

Many users describe the result as robotic or tinny, with high-pitched sounds frequently lost. Otarmeni takes a different approach: rather than routing around the damaged biology, it works to restore it.

How the Treatment Reaches the Inner Ear

Gene therapy works by delivering a functional copy of a defective gene into the cells that need it. Otarmeni uses a modified virus, an adeno-associated virus called AAV1, to carry a working OTOF gene into the cochlea’s inner hair cells. Once delivered, those cells can begin producing otoferlin for the first time. The therapy is administered through a small surgical incision using the same procedure used to place a cochlear implant, and given once per ear.

Because the OTOF gene is too large to fit inside a single viral carrier, Regeneron engineered two separate carriers, each delivering half. Inside the cell, the halves combine into a complete working gene. This dual-vector gene therapy design made it one of the more technically complex submissions the FDA has reviewed.

The agency approved Otarmeni just 61 days after Regeneron filed, tied for the fastest biological therapy approval in its modern history, through the Commissioner’s National Priority Voucher program built to accelerate reviews for rare diseases with no existing treatments.

What the Trial Data Showed

The FDA’s decision rested on a single ongoing multi-center trial enrolling 24 children between 10 months and 16 years old. Of the 20 evaluable patients, 80 percent gained measurable hearing, an outcome the agency confirmed does not occur without intervention in this condition. Eliot Shearer, a pediatric ear, nose, and throat specialist at Boston Children’s Hospital who helped lead the trial, told NBC News the results are “life-changing for families with children with hearing loss.”

Reported side effects included middle ear infection, nausea, dizziness, and procedural pain. The therapy is not suitable for patients whose anatomy prevents safe surgical access to the inner ear, or those who already carry a cochlear implant in the same ear. The FDA granted accelerated approval, meaning continued clearance depends on longer-term data confirming that hearing gains persist and produce measurable improvements in speech development and quality of life.

International Findings Point the Same Direction

One day before the FDA’s decision, a separate trial published results in the journal Nature. Conducted in China with 42 participants including adults, the study found its treatment restored hearing in 90 percent of patients. The protocol differed from Otarmeni’s, but the findings reinforced the same principle: restoring OTOF gene function can recover hearing in patients born without it.

Daniel Lee, director of pediatric otology and neurotology at Massachusetts Eye and Ear, told the New York Times: “We have now entered the era of biological treatment for inner ear hearing loss.” John Germiller, a pediatric ear surgeon at Children’s Hospital of Philadelphia, told the same publication that the field’s next target should be progressive hearing loss, where cochlear cells erode over time, with the goal of preserving remaining cells before the damage becomes irreversible.

A Medical Advance That Divides Opinion

Not everyone greets the approval as straightforward progress. Advocates within the Deaf community argue that framing deafness as a condition requiring a fix dismisses its standing as a cultural and linguistic identity.

Teresa Blankmeyer Burke, a bioethicist at Gallaudet University, has warned that widespread adoption of gene therapies could shrink the deaf population to the point where Deaf culture and sign language communities lose the mass needed to sustain themselves. Jaipreet Virdi, a historian of medicine and disability at the University of Victoria in Canada, told NPR the push carries an embedded assumption, that deafness is a problem, without seriously engaging those who reject that view.

For families whose children have no hearing at all, the calculation looks different. Travis’s mother, Sierra Smith, described the moment her son first heard her laugh as “the most surreal moment a mother can feel.” The FDA will hold a public meeting on June 4, 2026, to review the National Priority Voucher program’s criteria and implementation, with written comments accepted through June 29.

Enjoyed this article? Subscribe to our free newsletter for engaging stories, exclusive content, and the latest news.